These additions come as Fractyl is preparing for commercialization efforts outside the US and has started the company's first US clinical trial for its lead product candidate Revita DMR for the treatment of type 2 diabetes and fatty liver disease.
Revita DMR (duodenal mucosal resurfacing) is a minimally-invasive, outpatient procedural therapy designed to reverse insulin-resistant metabolic diseases, including type 2 diabetes and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), by addressing their root cause in the intestine.
The US pilot follows successful clinical trials in the European Union and South America, involving more than 200 patients.
These studies, which include randomised, multicenter trials, showed a single treatment with Revita DMR was well tolerated and appears capable of producing sustained reductions in blood glucose levels, insulin use, insulin resistance, liver fat and inflammation, and weight.
Borys brings more than 26 years of industry experience to her new role, having held positions in corporate strategy, commercial operations, global brand management, business technology, finance, and business consulting.
She has direct experience with Fractyl's core market of metabolic diseases; most recently leading Sanofi's multibillion dollar US diabetes biologics business.
Prior to Sanofi, Borys worked for Pfizer, Wyeth, and Arthur Andersen.
Dr. Lopez-Talavera has more than 20 years of experience in drug development for liver and gastrointestinal diseases.
Prior to joining Fractyl, Dr. Lopez-Talavera was chief medical officer at Enterome Biosciences.
Before these industry roles, Dr. Lopez-Talavera was assistant professor with the Divisions of Gastroenterology and Hepatology, and Endocrinology and Pathology at the University of Pittsburgh Medical Center.
He has been an author on more than 120 research publications and abstracts in hepatology and liver diseases.
Fractyl Laboratories is a private medical technology company based in Lexington, Mass. Fractyl is developing Revita DMR, a same-day, minimally invasive procedure to treat two highly prevalent metabolic diseases: type 2 diabetes and NAFLD/NASH.
The Revita DMR procedure harnesses breakthrough insights in the role of the duodenum in causing insulin resistance and metabolic diseases to develop novel interventions designed to restore metabolic health.
The Revita DMR System received a CE mark in the European Union in April 2016. It has been approved for investigational use by the Food and Drug Administration in the United States. The Revita DMR System may be available for investigational use in other regions.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients